567 related articles for article (PubMed ID: 33432230)
21. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.
Doedens AL; Rubinstein MP; Gross ET; Best JA; Craig DH; Baker MK; Cole DJ; Bui JD; Goldrath AW
Cancer Immunol Res; 2016 Sep; 4(9):799-811. PubMed ID: 27485135
[TBL] [Abstract][Full Text] [Related]
22. Amino acids and RagD potentiate mTORC1 activation in CD8
Zhang Y; Hu H; Liu W; Yan SM; Li Y; Tan L; Chen Y; Liu J; Peng Z; Yuan Y; Huang W; Yu F; He X; Li B; Zhang H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883257
[TBL] [Abstract][Full Text] [Related]
23. IL6 Induces an IL22
St Paul M; Saibil SD; Lien SC; Han S; Sayad A; Mulder DT; Garcia-Batres CR; Elford AR; Israni-Winger K; Robert-Tissot C; Zon M; Katz SR; Shaw PA; Clarke BA; Bernardini MQ; Nguyen LT; Haibe-Kains B; Pugh TJ; Ohashi PS
Cancer Immunol Res; 2020 Mar; 8(3):321-333. PubMed ID: 31964625
[TBL] [Abstract][Full Text] [Related]
24. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
25. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
26. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.
Zhou J; Kryczek I; Li S; Li X; Aguilar A; Wei S; Grove S; Vatan L; Yu J; Yan Y; Liao P; Lin H; Li J; Li G; Du W; Wang W; Lang X; Wang W; Wang S; Zou W
Nat Immunol; 2021 Apr; 22(4):460-470. PubMed ID: 33767425
[TBL] [Abstract][Full Text] [Related]
27. Ozone-Induced Aryl Hydrocarbon Receptor Activation Controls Lung Inflammation via Interleukin-22 Modulation.
Michaudel C; Bataille F; Maillet I; Fauconnier L; Colas C; Sokol H; Straube M; Couturier-Maillard A; Dumoutier L; van Snick J; Quesniaux VF; Togbe D; Ryffel B
Front Immunol; 2020; 11():144. PubMed ID: 32161582
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
29. Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
Eikawa S; Nishida M; Mizukami S; Yamazaki C; Nakayama E; Udono H
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1809-14. PubMed ID: 25624476
[TBL] [Abstract][Full Text] [Related]
30. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
31. Activin-A impedes the establishment of CD4
Morianos I; Tsitsopoulou A; Potaris K; Valakos D; Fari O; Vatsellas G; Bostantzoglou C; Photiades A; Gaga M; Xanthou G; Semitekolou M
J Exp Clin Cancer Res; 2021 Sep; 40(1):295. PubMed ID: 34548096
[TBL] [Abstract][Full Text] [Related]
32. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
[TBL] [Abstract][Full Text] [Related]
33. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
Beyranvand Nejad E; Labrie C; van Elsas MJ; Kleinovink JW; Mittrücker HW; Franken KLMC; Heink S; Korn T; Arens R; van Hall T; van der Burg SH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879600
[TBL] [Abstract][Full Text] [Related]
34. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
[TBL] [Abstract][Full Text] [Related]
35. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
36. IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model.
Lutz V; Hellmund VM; Picard FSR; Raifer H; Ruckenbrod T; Klein M; Bopp T; Savai R; Duewell P; Keber CU; Weigert A; Chung HR; Buchholz M; Menke A; Gress TM; Huber M; Bauer C
Cancer Immunol Res; 2023 Apr; 11(4):421-434. PubMed ID: 36758176
[TBL] [Abstract][Full Text] [Related]
37. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
39. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8
Seo H; Chen J; González-Avalos E; Samaniego-Castruita D; Das A; Wang YH; López-Moyado IF; Georges RO; Zhang W; Onodera A; Wu CJ; Lu LF; Hogan PG; Bhandoola A; Rao A
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12410-12415. PubMed ID: 31152140
[TBL] [Abstract][Full Text] [Related]
40. IL-36β Promotes CD8
Zhao X; Chen X; Shen X; Tang P; Chen C; Zhu Q; Li M; Xia R; Yang X; Feng C; Zhu X; Zhu Y; Sun Z; Zhang X; Lu B; Wang X
Front Immunol; 2019; 10():1803. PubMed ID: 31447838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]